Publications

  • How to Make Your Drug Launch a Success

    September 06, 2017 | Pharmaceuticals | Bain Brief

    Bain research shows successful pharmaceutical companies are overhauling their approach to drug launch—and they do three things right.

  • Pharma Investment 2017

    February 07, 2017 | Healthcare | The Deal | Media mention

    Kara Murphy, a partner with Bain & Company and co-lead of the healthcare private equity team, recently participated in a live webcast with The Deal on the topic of investment trends in pharma.

  • Reducing the Risk of Noncompliance in Healthcare

    July 27, 2016 | Bain Brief

    What’s changed? Compliance requirements around the world have multiplied since 2000. At the same time, pharma and medtech product portfolios and organizations have grown rapidly and become more complex. That combination has created a perfect storm in compliance for many leadership teams.

  • Growing influence of procurement officers over purchasing decisions in management-led healthcare organizations leaves physicians increasingly dissatisfied; less than one-third would recommend their organization to others

    June 05, 2015 | Healthcare | Press release

    GROWING INFLUENCE OF PROCUREMENT OFFICERS OVER PURCHASING DECISIONS IN MANAGEMENT-LED HEALTHCARE ORGANIZATIONS LEAVES PHYSICIANS INCREASINGLY DISSATISFIED; LESS THAN ONE-THIRD WOULD RECOMMEND THEIR ORGANIZATION TO OTHERS

  • A tale of two sectors

    May 17, 2011 | Financial Times | Media mention

    At first glance, few sectors appear more immune to austerity than the drugs business. Growing prosperity and advances in medical science are creating ever-rising demand for healthcare from an expanding global population that is living far longer than before.

  • The new cost-conscious doctor: Changing America's healthcare landscape

    March 03, 2011 | Healthcare | Bain Brief

    For those who believe that America's physicians contribute to the country's spiraling healthcare costs by demanding more—more unnecessary tests, more expensive prescriptions, more complex treatment regimens—change is on the way.

  • The real reason big pharma mergers are wise

    June 25, 2009 | Acquisition Strategy, Healthcare | Forbes.com

    The giants of the pharmaceutical industry may have found their salvation in the wave of consolidation that's changing the face of the industry. But not for the reasons that have been used to justify Pfizer's acquisition of Wyeth, Merck's purchase of Schering-Plough and Genentech's deal with Roche.

  • A cancer for drug makers

    June 20, 2006 | Healthcare | The Wall Street Journal Europe

    The battle over Herceptin, the drug for breast cancer that this month won preliminary approval for broader use from U.K. health regulators, was a bruising affair that focused public attention on the high price of a shot at survival.